Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-defining trial of tolvaptan in pediatric congestive heart failure with volume overload
jRCT2080223618Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in heart failure (HF) and hypervolemia, sponsored by Otsuka Pharmaceutical Co., Ltd. Started Aug 2017; status: completed.
02
Drugs
tolvaptan
03
Conditions
heart failure (HF)hypervolemia
Beyond the preview
Go deeper on jRCT2080223618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223618.